All News
The RheumNow Week in Review – 6 January 2017
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
Read Article
Biopsy Proven Renal Involvement in Sjogren's Syndrome
A French multicenter study of primary Sjogren's syndrome (pSS) patients fulfilling the American–European Consensus Group criteria or enlarged American–European Consensus Group criteria were retrospectively studied based on having biopsy-proven renal involvement.
Read Article
DMARDs Under Study for Secondary Prevention of Cardiovascular Events
Several important lines of population and large cohort research have shown that rheumatoid arthritis (RA) patients have a substantially higher risk for myocardial infarction and major cardiovascular events.
Read Article
RheumNow Week in Review – 16 December 2016
Dr. Jack Cush reviews highlights from this week on RheumNow.com
Read Article
EULAR 2016 Recommendations on Early Arthritis
Combe and leading European rheumatologist have published an update to the 2007 European League Against Rheumatism (EULAR) recommendations for management of early arthritis.
Read Article
Lupus May Be at Increased Risk for Dementia
Neuropsychiatric manifestations of systemic lupus erythematosus (SLE) may occur in up to half of patients in their lifetime.
However, dementia is often not reported or studied in cohorts with neurologic disease in lupus.
Read Article
Random Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes
Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients.
Read Article
The RheumNow Week in Review – 2 December 2016
Dr. Cush highlights reports from this week on RheumNow.com.
Read Article
Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial
Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.
Read Article
Ustekinumab Effective and Safe in Crohn's Colitis
The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)
Read Article
Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Read Article
Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial
Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.
Read Article
Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Read Article
Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Read Article
Janssen's Portfolio of New Biologics Roll Out for ACR 2016
Janssen has announced the listings for it's presentations at the upcoming annual ACR/ARHP 2016 meeting in Washington.
Read Article
RheumNow Week in Review – 4 November 2016
Dr. Jack Cush reviews highlights and reports from this week on RheumNow.com, including drug-induced cutaneous lupus, pediatric lupus being worse, new gout drug SEL-12, Gut microbiome and IgA plasmablasts, and the weakly-received new ACP guidelines on gout.
Read Article
Lymphotoxin B and Adipose Derived Stromal Cells Regulate Skin Fibrosis in Scleroderma
A possible mechanism behind the fibrosis that occurs in scleroderma has now been identified, a mechanism, researchers say, that may one day lead to a treatment for the disease.
IgA ACPA and Plasmablasts Point to Microbiome in Pre-Clinical Rheumatoid
Serum antibodies precede the development of clinical rheumatoid arthritis (RAby) by many years, and yet we still have much to learn about this preclinical phase.
Read Article
Is There a Familial Risk to Scleroderma?
Using population based data, researchers found a 10 fold increase prevalence of SSc in first degree relatives. That equates to a relative risk of 81. Genetic factors appear to be important in the risk for scleroderma.
Read Article
